191 related articles for article (PubMed ID: 36070626)
1. Vaccination with human alphapapillomavirus-derived L2 multimer protects against human betapapillomavirus challenge, including in epidermodysplasia verruciformis model mice.
Olczak P; Wong M; Tsai HL; Wang H; Kirnbauer R; Griffith AJ; Lambert PF; Roden R
Virology; 2022 Oct; 575():63-73. PubMed ID: 36070626
[TBL] [Abstract][Full Text] [Related]
2. RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer.
Olczak P; Matsui K; Wong M; Alvarez J; Lambert P; Christensen ND; Hu J; Huber B; Kirnbauer R; Wang JW; Roden RBS
J Virol; 2022 Jul; 96(13):e0056622. PubMed ID: 35703545
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses.
Schellenbacher C; Kwak K; Fink D; Shafti-Keramat S; Huber B; Jindra C; Faust H; Dillner J; Roden RBS; Kirnbauer R
J Invest Dermatol; 2013 Dec; 133(12):2706-2713. PubMed ID: 23752042
[TBL] [Abstract][Full Text] [Related]
4. Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types.
Kwak K; Jiang R; Wang JW; Jagu S; Kirnbauer R; Roden RB
PLoS One; 2014; 9(5):e97232. PubMed ID: 24816794
[TBL] [Abstract][Full Text] [Related]
5. Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine.
Jagu S; Kwak K; Schiller JT; Lowy DR; Kleanthous H; Kalnin K; Wang C; Wang HK; Chow LT; Huh WK; Jaganathan KS; Chivukula SV; Roden RB
J Virol; 2013 Jun; 87(11):6127-36. PubMed ID: 23536682
[TBL] [Abstract][Full Text] [Related]
6. Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).
Huber B; Schellenbacher C; Shafti-Keramat S; Jindra C; Christensen N; Kirnbauer R
PLoS One; 2017; 12(1):e0169533. PubMed ID: 28056100
[TBL] [Abstract][Full Text] [Related]
7. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
8. A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.
Huber B; Schellenbacher C; Jindra C; Fink D; Shafti-Keramat S; Kirnbauer R
PLoS One; 2015; 10(3):e0120152. PubMed ID: 25790098
[TBL] [Abstract][Full Text] [Related]
9. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
10. Mixed Bacteriophage MS2-L2 VLPs Elicit Long-Lasting Protective Antibodies against HPV Pseudovirus 51.
Yadav R; Zhai L; Kunda NK; Muttil P; Tumban E
Viruses; 2021 Jun; 13(6):. PubMed ID: 34200586
[TBL] [Abstract][Full Text] [Related]
11. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
Jagu S; Karanam B; Gambhira R; Chivukula SV; Chaganti RJ; Lowy DR; Schiller JT; Roden RB
J Natl Cancer Inst; 2009 Jun; 101(11):782-92. PubMed ID: 19470949
[TBL] [Abstract][Full Text] [Related]
12. Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes.
Kalnin K; Chivukula S; Tibbitts T; Yan Y; Stegalkina S; Shen L; Cieszynski J; Costa V; Sabharwal R; Anderson SF; Christensen N; Jagu S; Roden RBS; Kleanthous H
Vaccine; 2017 Sep; 35(37):4942-4951. PubMed ID: 28778613
[TBL] [Abstract][Full Text] [Related]
13. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.
Jagu S; Karanam B; Wang JW; Zayed H; Weghofer M; Brendle SA; Balogh KK; Tossi KP; Roden RBS; Christensen ND
Vaccine; 2015 Oct; 33(42):5553-5563. PubMed ID: 26382603
[TBL] [Abstract][Full Text] [Related]
14. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.
Gambhira R; Jagu S; Karanam B; Gravitt PE; Culp TD; Christensen ND; Roden RB
J Virol; 2007 Nov; 81(21):11585-92. PubMed ID: 17715230
[TBL] [Abstract][Full Text] [Related]
15. Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation.
Kwak K; Jiang R; Jagu S; Wang JW; Wang C; Christensen ND; Roden RB
PLoS One; 2013; 8(3):e60507. PubMed ID: 23536912
[TBL] [Abstract][Full Text] [Related]
16. Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?
Yadav R; Zhai L; Tumban E
Viruses; 2019 Dec; 12(1):. PubMed ID: 31877975
[TBL] [Abstract][Full Text] [Related]
17. Utility of the Human Papillomavirus Vaccination in Management of HPV-associated Cutaneous Lesions.
Gay J; Johnson N; Kavuru V; Phillips M
Skin Therapy Lett; 2021 Mar; 26(2):6-8. PubMed ID: 33769773
[TBL] [Abstract][Full Text] [Related]
18. Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer.
Zhai L; Yadav R; Kunda NK; Anderson D; Bruckner E; Miller EK; Basu R; Muttil P; Tumban E
Antiviral Res; 2019 Jun; 166():56-65. PubMed ID: 30926288
[TBL] [Abstract][Full Text] [Related]
19. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
20. Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes.
Kalnin K; Tibbitts T; Yan Y; Stegalkina S; Shen L; Costa V; Sabharwal R; Anderson SF; Day PM; Christensen N; Schiller JT; Jagu S; Roden RB; Almond J; Kleanthous H
Vaccine; 2014 Jun; 32(28):3540-7. PubMed ID: 24780250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
